Mostrar el registro sencillo del ítem

Artículo

dc.creatorBabu Rajendran, N.es
dc.creatorMutters, Nico Tomes
dc.creatorMarasca, Giuseppees
dc.creatorConti, Michelaes
dc.creatorSifakis, Frangiscos G.es
dc.creatorVuong, Cuonges
dc.creatorRodríguez-Baño, Jesúses
dc.creatorTacconelli, Evelinaes
dc.date.accessioned2023-04-04T09:56:15Z
dc.date.available2023-04-04T09:56:15Z
dc.date.issued2020
dc.identifier.citationBabu Rajendran, N., Mutters, N.T., Marasca, G., Conti, M., Sifakis, F.G., Vuong, C.,...,Tacconelli, E. (2020). Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. Clinical Microbiology and Infection, 26 (7), 943 e1-943 e6. https://doi.org/10.1016/j.cmi.2019.11.020.
dc.identifier.issn1198-743Xes
dc.identifier.issn1469-0691(electrónico)es
dc.identifier.urihttps://hdl.handle.net/11441/143915
dc.description.abstractObjectives: In 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states. Methods: Compulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only. Results: Twenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen. Conclusions: Our review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings.es
dc.formatapplication/pdfes
dc.format.extent6 p.es
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofClinical Microbiology and Infection, 26 (7), 943 e1-943 e6.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAntimicrobial resistancees
dc.subjectEuropees
dc.subjectMandatoryes
dc.subjectPublic healthes
dc.subjectReportinges
dc.subjectSurveillancees
dc.titleMandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countrieses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDFP7/2007-2013es
dc.relation.projectID115737es
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1198743X19306202?via%3Dihubes
dc.identifier.doi10.1016/j.cmi.2019.11.020es
dc.journaltitleClinical Microbiology and Infectiones
dc.publication.volumen26es
dc.publication.issue7es
dc.publication.initialPage943 e1es
dc.publication.endPage943 e6es
dc.contributor.funderEFPIA companieses
dc.contributor.funderInnovative Medicines Initiative Joint Undertaking from the European Union Seventh Framework Programmees

FicherosTamañoFormatoVerDescripción
Mandatory surveillance and ...584.0KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional